EVO-101

N/A

Report date: 2025/08/20 10:41:54
NME

Base Information

Drug NameEVO-101
Drug Alias NameEVO-101
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-1 receptor-associated kinase 4 inhibitors
TargetsInterleukin-1 receptor-associated kinase 4
Therapy Area/IndicationsEczemaSkin DiseasesDermatitis, Atopic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEvommune Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Clinical Research IncEvommune Inc
Inactive CompaniesN/A
Active IndicationsEczemaHidradenitis Suppurativa
Inactive IndicationsSkin DiseasesDermatitis, Atopic

Other Information

ATC CodeN/A
Related LinksN/A